1. Home
  2. NUVL vs WULF Comparison

NUVL vs WULF Comparison

Compare NUVL & WULF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$104.60

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Logo TeraWulf Inc.

WULF

TeraWulf Inc.

HOLD

Current Price

$23.28

Market Cap

6.8B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
WULF
Founded
2017
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.3B
6.8B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
NUVL
WULF
Price
$104.60
$23.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
11
Target Price
$134.75
$20.86
AVG Volume (30 Days)
506.3K
28.8M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$168,455,000.00
Revenue This Year
N/A
$126.80
Revenue Next Year
$1,239.49
$162.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.28
52 Week Low
$70.25
$3.45
52 Week High
$113.02
$25.75

Technical Indicators

Market Signals
Indicator
NUVL
WULF
Relative Strength Index (RSI) 53.04 62.32
Support Level $97.91 $11.30
Resistance Level $107.49 N/A
Average True Range (ATR) 3.83 1.52
MACD -0.18 0.23
Stochastic Oscillator 56.63 63.00

Price Performance

Historical Comparison
NUVL
WULF

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About WULF TeraWulf Inc.

TeraWulf Inc is a digital asset technology company that is engaged in digital infrastructure and sustainable energy development. It is involved in supporting environmentally conscious bitcoin mining operations by developing and operating facilities within the United States. The company's bitcoin mining facilities are powered by clean, affordable, and reliable energy sources. Its primary source of revenue stems from the mining of bitcoin conducted at the company's mining facility sites. Additionally, the company occasionally generates revenue through the provision of miner hosting services to third-party entities.

Share on Social Networks: